Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

Phase III HELIOS-B trial found that Amvuttra (vutrisiran) also preserved functional capacity and quality of life in patients ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aortic stenosis (AS) fared particularly poorly in a large ...

The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. There are fewer laptop deals available to kick off 2025 but I've still found some strong ...

for ATTR amyloidosis with cardiomyopathy (ATTR-CM), and MAGNITUDE-2 (NCT06672237), for patients with hereditary ATTR amyloidosis with polyneuropathy. Patient recruitment for MAGNITUDE is ongoing, with ...

DNA analysis of TTR gene to detect or exclude hereditary transthyretin-related amyloidosis (ATTR). - Serum free light chain assay to detect low grade plasma-cell dyscrasia. - Mass spectrometry for ...

Vutrisiran – an RNAi therapeutic marketed in various countries globally as a treatment of adults with hATTR amyloidosis ... polyneuropathy, and in development for the treatment of adults with ...

The phase III MAGNITUDE 2 study is actively screening patients with hereditary ATTR amyloidosis with polyneuropathy, with the first patient expected to be dosed later in the first quarter of 2025.